COEP Coeptis Therapeutics
- 0.360
- -0.010-2.60%
- 0.368
- +0.008+2.22%
Coeptis Therapeutics News
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
WEXFORD, Pa., May 2, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award
WEXFORD, Pa., April 2, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms fo
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersApollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. Cara Therapeutics (NASDAQ:CARA) share
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersGeron (NASDAQ:GERN) stock increased by 90.8% to $3.34 during Thursday's after-market session. The market value of their outstanding shares is at $1.8 billion. Madrigal Pharmaceuticals (NASDAQ:M
Coeptis Expands License for CAR Technology to Autoimmune Diseases
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), a biopharmaceutical company, announced today an expansion of its exclusive license agreement with the University of Pittsburgh.
Coeptis Therapeutics Adds Autoimmune Indications To Exclusive License Agreement With University Of Pittsburgh For SNAP-CAR T And SNAP-CAR NK
Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune di
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement With University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune di
Biotech With Potential: Coeptis Therapeutics (COEP) And 3 Underrated Gems
12 Health Care Stocks Moving In Monday's After-Market Session
GainersBioSig Technologies (NASDAQ:BSGM) stock increased by 7.7% to $0.96 during Monday's after-market session. The company's market cap stands at $8.9 million. Coeptis Therapeutics (NASDAQ:COEP) shar
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which can severely reduce immune cells leading to hospitalization and deathWEXFORD,
Collective Audience And 3 Other Stocks Under $1 Insiders Are Buying
The Dow Jones index closed lower by around 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and trader
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersTalphera (NASDAQ:TLPH) stock moved upwards by 10.5% to $0.85 during Wednesday's after-market session. The company's market cap stands at $14.4 million. Windtree Therapeutics (NASDAQ:WINT) share
Coeptis Therapeutics(COEP.US) Officer Buys US$3,350 in Common Stocks
$Coeptis Therapeutics(COEP.US)$ Officer Cogley Brian purchased 5,000 shares of Common Stocks on Jan 10, 2024 at an average price of $0.67 for a total value of $3,350.Source: Announcement(one of the fo
Coeptis Therapeutics(COEP.US) Director Buys US$1,304.96 in Common Stocks
$Coeptis Therapeutics(COEP.US)$ Director DeSilva Tara purchased 2,266 shares of Common Stocks on Jan 12, 2024 at an average price of $0.58 for a total value of $1,304.96.Source: Announcement What is s
Coeptis Therapeutics(COEP.US) 10% Shareholder Buys US$16,747.14 in Common Stocks
$Coeptis Therapeutics(COEP.US)$ 10% Shareholder Mehalick David purchased 25,054 shares of Common Stocks on Jan 5, 8, 2024 at an average price of $0.67 for a total value of $16,747.14.Source: Announcem
Coeptis Therapeutics(COEP.US) Director Buys US$8,004 in Common Stocks
$Coeptis Therapeutics(COEP.US)$ Director Salkind Gene purchased 11,600 shares of Common Stocks on Jan 5, 2024 at an average price of $0.69 for a total value of $8,004.Source: Announcement What is stat
Coeptis Therapeutics(COEP.US) Officer Buys US$7,486.5 in Common Stocks
$Coeptis Therapeutics(COEP.US)$ Officer Yerace Daniel Alexander purchased 10,850 shares of Common Stocks on Jan 5, 2024 at an average price of $0.69 for a total value of $7,486.5.Source: Announcement
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024
WEXFORD, Pa., Jan. 4, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for
Coeptis Therapeutics to Present at the Emerging Growth Conference
WEXFORD, Pa., Dec. 4, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for
Buy Rating for Coeptis Therapeutics Holdings Amidst Promising Cancer Cell Therapy Platforms and Exclusive Licensing Assets
Analysis
Price Target
No Data
